Application of echinacoside in the preparation of drugs for the prevention or treatment of demyelinating diseases
Echinacea glycoside (ECH) improves myelin structure by promoting oligodendrocyte differentiation and proliferation, thus addressing the limited efficacy of existing treatments for demyelinating diseases. It achieves myelin regeneration and nerve function recovery, significantly improving motor function.
Patent Information
- Application Number
- CN202610546290.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-23
- Publication Date
- 2026-07-14
AI Technical Summary
Existing treatments for demyelinating diseases have limited efficacy, significant adverse reactions, and cannot effectively promote myelin repair and nerve function recovery. Currently, there are no reports on the role of echinacoside in myelin repair.
Echinacea glycoside (ECH) was used to promote the differentiation, maturation, and proliferation of oligodendrocytes (OLs), improve myelin ultrastructure, reduce myelin damage, and promote myelin regeneration. Different doses of ECH were administered to mice to treat the disease.
It significantly improved the differentiation and proliferation of oligodendrocytes, improved myelin sheath thickness, reduced myelin loss and axonal pathological damage, enhanced nerve conduction function, improved motor coordination and gait function, and provided a new treatment method for demyelinating diseases.
Smart Images

Figure CN122376606A_ABST
